

# A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

**Status:** RECRUITING

## Eligibility Criteria

**Age:** 18 years and over

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

### Inclusion Criteria:

\* Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria \* Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment \* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 \* A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment \* A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment

### Exclusion Criteria:

\* Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams \[mg\] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to ( $\geq$ ) 20 mg of dexamethasone within 14 days before randomization \* Had plasmapheresis within 28 days of randomization \* Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization \* Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients \* Known contraindications to the use of daratumumab or lenalidomide per local prescribing information \* Myeloma Frailty Index of  $\geq 2$  with the exception of participants who have a score of 2 based on age alone

## Conditions & Interventions

### Interventions:

DRUG: Teclistamab, DRUG: Daratumumab, DRUG: Lenalidomide, DRUG: Dexamethasone, DRUG: Talquetamab

### Conditions:

Multiple Myeloma

## More Information

**Contact(s):** Study Contact - Participate-In-This-Study1@its.jnj.com

**Principal Investigator:**

**IRB**

**Number:**

**System ID:** NCT05552222

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact [ctrrecruit@vcu.edu](mailto:ctrrecruit@vcu.edu) if you have questions or need assistance.